There is evidence that Actelion and Johnson & Johnson are edging closer to a deal to give the U.S. drugmaker control of the Swiss biotech, sort of.

Drugmakers shelled out twice as much for acquisitions in 2016 as they did in 2015—and it wasn’t because those buys were twice as valuable.

Would-be deal partners Johnson & Johnson and Actelion are onto their second round of talks, and this time, Actelion may just get the transaction it’s been…

If there’s one word that describes 2016’s pharma M&A market, it’s “slow.” And in 2017, no one’s expecting big changes fast, despite the advent of a new…

While most analysts seems to think that the Biogen's pick for CEO suggests the company is not interested in a buyout, they indicated, there is always a…

Just a few days after Johnson & Johnson formally bowed out of its Actelion takeover effort, Sanofi is reportedly nearing a deal for the Swiss drugmaker.

Pfizer rolled out the first round of new data since it closed on Xtandi-maker Medivation in September—and the results weren’t good.

The FDA Wednesday approved an eczema treatment developed by Anacor, which Pfizer bought in June, that is projected to be a $2 billion blockbuster.

J&J abandoned its bid for Actelion Tuesday, but another buyer is talking with the Swiss biotech—and according to multiple media reports, Sanofi is it. Next…

M&A